Nektar Therapeutics

NasdaqCM:NKTR Rapporto sulle azioni

Cap. di mercato: US$226.4m

Nektar Therapeutics Gestione

Gestione criteri di controllo 3/4

Nektar Therapeutics Il CEO è Howard Robin, nominato in Jan2007, e ha un mandato di 17.83 anni. la retribuzione annua totale è $ 3.14M, composta da 34.6% di stipendio e 65.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.37% delle azioni della società, per un valore di $ 828.73K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 16.3 anni.

Informazioni chiave

Howard Robin

Amministratore delegato

US$3.1m

Compenso totale

Percentuale dello stipendio del CEO34.6%
Mandato del CEO17.8yrs
Proprietà del CEO0.4%
Durata media del management5.8yrs
Durata media del Consiglio di amministrazione16.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Oct 18
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

Jun 19
Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31
Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nov 06
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Apr 24
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11
We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline

Apr 04

Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts

Mar 09
Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts

Nektar Therapeutics: Beaten Down By 2020

Jan 26

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Howard Robin rispetto agli utili di Nektar Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$177m

Mar 31 2024n/an/a

-US$176m

Dec 31 2023US$3mUS$1m

-US$276m

Sep 30 2023n/an/a

-US$294m

Jun 30 2023n/an/a

-US$307m

Mar 31 2023n/an/a

-US$415m

Dec 31 2022US$11mUS$1m

-US$368m

Sep 30 2022n/an/a

-US$454m

Jun 30 2022n/an/a

-US$525m

Mar 31 2022n/an/a

-US$491m

Dec 31 2021US$11mUS$1m

-US$524m

Sep 30 2021n/an/a

-US$495m

Jun 30 2021n/an/a

-US$474m

Mar 31 2021n/an/a

-US$429m

Dec 31 2020US$11mUS$1m

-US$444m

Sep 30 2020n/an/a

-US$439m

Jun 30 2020n/an/a

-US$429m

Mar 31 2020n/an/a

-US$460m

Dec 31 2019US$10mUS$1m

-US$441m

Sep 30 2019n/an/a

-US$427m

Jun 30 2019n/an/a

-US$424m

Mar 31 2019n/an/a

US$657m

Dec 31 2018US$13mUS$969k

US$681m

Sep 30 2018n/an/a

US$746m

Jun 30 2018n/an/a

US$903m

Mar 31 2018n/an/a

-US$129m

Dec 31 2017US$18mUS$941k

-US$97m

Compensazione vs Mercato: La retribuzione totale di Howard ($USD 3.14M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.48M ).

Compensazione vs guadagni: La retribuzione di Howard è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Howard Robin (71 yo)

17.8yrs

Mandato

US$3,135,576

Compensazione

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Howard Robin
CEO, President & Director17.8yrsUS$3.14m0.37%
$ 828.7k
Sandra Gardiner
Chief Financial Officer1.6yrsUS$376.30kNessun dato
Mark Wilson
Senior VP8.3yrsUS$1.10m0.12%
$ 277.1k
Jonathan Zalevsky
Chief Research & Development Officer5.1yrsUS$1.77m0.14%
$ 308.5k
Vivian Wu
Director of Investor Relations & Corporate Affairsno dataNessun datoNessun dato
Robert Bacci
Senior Vice President of Human Resources & Facilities Operations2.9yrsNessun datoNessun dato
Jennifer Ruddock
Chief Business Officer5.8yrsNessun datoNessun dato
Mary Tagliaferri
Chief Medical Officer7yrsNessun datoNessun dato

5.8yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di NKTR è esperto e expertise (durata media dell'incarico 5.8 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Howard Robin
CEO, President & Director17.8yrsUS$3.14m0.37%
$ 828.7k
Robert Chess
Independent Chairman of the Board32.5yrsUS$176.22k0.14%
$ 321.7k
R. Greer
Independent Director14.8yrsUS$170.22k0.16%
$ 373.4k
Roy Whitfield
Lead Independent Director24.3yrsUS$170.22k0.16%
$ 353.9k
Jeffrey Ajer
Independent Director7.2yrsUS$134.22k0.019%
$ 42.0k
Diana Brainard
Independent Director3yrsUS$112.72k0.012%
$ 27.6k

16.3yrs

Durata media

66.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di NKTR è composto da personale esperto e esperto (durata media dell'incarico 16.3 anni).